1. Introduction {#sec1-ijms-19-00073}
===============

Various adipokines, including adiponectin, adipsin, apelin, chemerin, fibroblast growth factor 21, interleukin-6 (IL-6), leptin, retinol-binding protein 4, osteonectin, omentin, plasminogen activator inhibitor-1, progranulin, resistin, tumor necrosis factor (TNF), vaspin, and vistafin are derived from the adipose tissue \[[@B1-ijms-19-00073],[@B2-ijms-19-00073]\].

Adipokines participate in various physiological and pathological processes including insulin sensitivity, energy expenditure, glucose and lipid metabolism, inflammatory activity, neuroendocrine activity, immunity, cancer, homeostasis, angiogenesis, cardiovascular function, breeding and bone metabolism, and all functions of the endocrine-reproductive system axis \[[@B2-ijms-19-00073],[@B3-ijms-19-00073],[@B4-ijms-19-00073]\]. The majority of adipokines, such as TNF-α and IL-6, pose adverse effects and aggravate the severity of diseases \[[@B5-ijms-19-00073],[@B6-ijms-19-00073]\]. On the contrary, a few of these, such as adiponectin and omentin, are "good" adipokines \[[@B7-ijms-19-00073],[@B8-ijms-19-00073]\]. Omentin is an important molecule that connects organs with adipose tissue and exerts extensive protective effects \[[@B9-ijms-19-00073],[@B10-ijms-19-00073]\]. Pulmonary diseases are devastating disorders with high morbidity and mortality, and understanding the cellular and molecular mechanisms of omentin function in these diseases is a key step towards improving research on pulmonary disease biology. Therefore, this review focuses on the latest advances in omentin biology and its effects on the development and progression of pulmonary diseases.

2. The Structure and Development of Omentin {#sec2-ijms-19-00073}
===========================================

Omentin is a novel hydrophilic adipokine of 313 amino acids (35 kDa), which contains a secretory signal sequence and a fibrinogen-related domain, and appears as a glycolized trimer of 120 kDa molecular weight in its negative form \[[@B10-ijms-19-00073],[@B11-ijms-19-00073]\]. In 2005, omentin was officially depicted in an omental fat cDNA library with Uniprot code Q8WWAO and Genbank accession number AY549722 \[[@B12-ijms-19-00073]\]; it was initially identified in intestinal Paneth cells and endothelial cells with the name intelectin-1, intestinal lactoferrin receptor, galactofuranose binding lectin, and endothelial lectin \[[@B13-ijms-19-00073],[@B14-ijms-19-00073]\]. However, specific receptors for omentin have not yet been identified. Omentin-1 and omentin-2 are two highly homologous isoforms with 83% amino acid identity, the genes encoding which are proximal to the 1q22--q23 chromosomal region associated with type-2 diabetes mellitus (T2DM) in many individuals \[[@B12-ijms-19-00073],[@B15-ijms-19-00073]\]. Omentin-1 is the major circulating form with a concentration of 100 ng/mL to 1 μg/mL in human plasma, and has been more extensively studied than omentin-2 \[[@B10-ijms-19-00073]\]. Omentin-1 is a Ca^2+^-dependent galactofuranose-binding lectin used for identifying bacterial components, and is important for defense against pathogenic bacteria \[[@B12-ijms-19-00073],[@B13-ijms-19-00073]\]. In the following sections, we will refer to omentin-1 or intelectin-1 as omentin.

3. The Concentration of Omentin Fluctuates in Various Diseases {#sec3-ijms-19-00073}
==============================================================

In recent years, considerable progress has been made in determining and characterizing the effects of omentin on different diseases. Based on a large number of epidemiological, clinical, and laboratory analyses, the changes in omentin levels in various diseases have been summarized in [Table 1](#ijms-19-00073-t001){ref-type="table"}.

Omentin levels are inversely related to obesity and positively to adiponectin levels \[[@B16-ijms-19-00073]\]. Several studies have shown that higher omentin levels were associated with leanness or acted as a positive factors against obesity \[[@B16-ijms-19-00073],[@B17-ijms-19-00073],[@B18-ijms-19-00073]\]. Reports also showed that pre-existing obese pregnant women had lower omentin levels in the placenta and adipose tissue than their normal weight counterparts \[[@B19-ijms-19-00073]\]. In addition, studies indicated that the serum levels of omentin were low in patients with impaired glucose regulation, T2DM \[[@B20-ijms-19-00073]\], gestational diabetes mellitus (GDM) \[[@B21-ijms-19-00073]\], T2DM with ischemic heart disease \[[@B22-ijms-19-00073],[@B23-ijms-19-00073]\], and diabetic retinopathy \[[@B24-ijms-19-00073]\]. Recent reports showed that circulating omentin levels in women with polycystic ovary syndrome (PCOS) were significantly lower than that in normal women, independent of body mass \[[@B25-ijms-19-00073],[@B26-ijms-19-00073]\]. Moreover, the results of a meta-analysis \[[@B27-ijms-19-00073]\] including 1264 subjects (733 patients with PCOS and 531 controls) showed a significant decrease in circulating omentin levels in patients with PCOS. Serum omentin levels apparently increased in PCOS individuals after administration of metformin. These prompted the speculation that omentin may play a significant role in the pathogenesis of PCOS \[[@B28-ijms-19-00073]\].

Several studies demonstrated a significant reduction in omentin levels in various cardiovascular diseases, including patients with carotid atherosclerosis \[[@B29-ijms-19-00073],[@B30-ijms-19-00073],[@B31-ijms-19-00073]\], coronary artery disease (CAD) \[[@B32-ijms-19-00073],[@B33-ijms-19-00073]\], heart failure \[[@B34-ijms-19-00073]\], and dilated cardiomyopathy \[[@B35-ijms-19-00073]\]. Another study demonstrated that omentin increased in the epicardial adipose tissue (EAT) but decreased in plasma in patients with CAD \[[@B32-ijms-19-00073]\]. Harada explained this contradictory phenomenon by postulating that the high levels of omentin isolated from the EAT in myocardial ischemia may exert a cardioprotective effect \[[@B32-ijms-19-00073]\]. Surprisingly, recent studies showed that omentin levels were elevated in nonalcoholic fatty liver disease (NAFLD) \[[@B36-ijms-19-00073]\], an obesity-related disease, although obesity is associated with low levels of omentin. More studies are warranted to elucidate the mechanisms underlying these contradictory observations.

Omentin levels were reduced in certain autoimmune diseases, including psoriasis \[[@B37-ijms-19-00073],[@B38-ijms-19-00073],[@B39-ijms-19-00073]\], rheumatoid arthritis \[[@B40-ijms-19-00073],[@B41-ijms-19-00073]\], Behcet's disease \[[@B42-ijms-19-00073]\], Crohn's disease \[[@B43-ijms-19-00073]\], ulcerative colitis \[[@B44-ijms-19-00073]\], chronic periodontitis \[[@B45-ijms-19-00073]\], and acute or chronic pancreatitis \[[@B46-ijms-19-00073]\]. Other studies demonstrated that omentin levels were highly elevated in individuals with psoriatic arthritis compared to individuals with psoriasis alone or healthy individuals \[[@B47-ijms-19-00073]\], although the precise mechanism underlying these observations is not obvious. In contrast, other research groups demonstrated that the presence of nephritis was associated with elevated plasma omentin levels in patients with systemic lupus erythematosus (SLE) \[[@B48-ijms-19-00073]\]. In addition, Peraire \[[@B49-ijms-19-00073]\] demonstrated that human immunodeficiency virus/highly active anti-retroviral therapy (HIV/HAART)-associated lipodystrophy syndrome (HALS) was related to decreased omentin levels in plasma, indicating that omentin may be an important contact between HIV/HAART and fat redistribution syndromes. Furthermore, the circulating levels of omentin were significantly lower in painful temporo-mandibular disorders (TMD), which may be mediated by inflammatory pathways \[[@B50-ijms-19-00073]\].

In addition, circulating omentin levels were also dramatically reduced in renal cell cancer \[[@B51-ijms-19-00073]\]; however, other cancers, such as malignant pleural mesothelioma (MPM) \[[@B52-ijms-19-00073]\], hepatic carcinoma \[[@B53-ijms-19-00073]\], prostate cancer \[[@B54-ijms-19-00073]\], colon and colorectal cancer \[[@B55-ijms-19-00073],[@B56-ijms-19-00073]\], gastric cancer \[[@B57-ijms-19-00073]\], and pancreatic adenocarcinoma \[[@B58-ijms-19-00073]\] were associated with increased omentin levels. Omentin may have an anti-cancer effect property where omentin can influence two types of human hepatocellular carcinoma cells: HepG2 and HuH-7. Omentin significantly inhibited the proliferation and promoted apoptosis of HepG2 and HuH-7 cells via activating the Jun N-terminal kinase (JNK)-p53 signaling pathway \[[@B53-ijms-19-00073]\]. Moreover, omentin can accelerate the apoptosis of hepatocellular carcinoma cells (HCC) by increasing the bax/bacl-2 ratio and inducing capases-3 activation \[[@B53-ijms-19-00073]\]. Subsequently, studies were conducted to investigate the effect of omentin in the respiratory system. A study demonstrated that circulating omentin levels were also dramatically decreased in patients with acute respiratory distress syndrome (ARDS) \[[@B59-ijms-19-00073]\]. Omentin may play an important role in defense against pathogenic bacteria, and lower omentin levels in smokers may contribute to increased susceptibility to infection \[[@B60-ijms-19-00073]\]. However, the results obtained with patients exhibiting obstructive sleep apnea syndrome (OSAS) were controversial. Wang et al. observed that serum omentin levels were significantly lower in patients with OSAS \[[@B61-ijms-19-00073]\], while two other groups showed that these patients had considerably higher omentin levels \[[@B62-ijms-19-00073],[@B63-ijms-19-00073]\]. The researchers also observed that omentin levels increased in airway epithelial cells of asthmatic individuals and speculated that omentin may be involved in the pathogenesis of asthma \[[@B64-ijms-19-00073],[@B65-ijms-19-00073]\].

The serum levels of omentin were also significantly higher in other diseases, such as liver cirrhosis \[[@B66-ijms-19-00073]\] and anorexia nervosa \[[@B67-ijms-19-00073],[@B68-ijms-19-00073]\], and in individuals undergoing hemodialysis with end stage renal disease \[[@B69-ijms-19-00073]\].

4. Protective Effects of Omentin in Various Pathophysiological Processes {#sec4-ijms-19-00073}
========================================================================

Omentin is an important component that connects organs with adipose tissue and exerts extensive protective effects via various cell signaling pathways during physiological and pathological processes ([Figure 1](#ijms-19-00073-f001){ref-type="fig"}). Yamawaki et al. indicated that omentin inhibited TNF-α-induced cyclooxygenase-2 (COX-2) expression via activation of adenosine 5′-monophosphate-activated protein kinase (AMPK), which further activated the endothelial nitric oxide synthase (eNOS)/NO pathway and blocked Jun N-terminal kinase (JNK) signaling, thereby playing an anti-inflammatory role in endothelial cells \[[@B70-ijms-19-00073]\]. Moreover, the activation of eNOS/NO induced vasodilation in isolated blood vessels \[[@B71-ijms-19-00073]\] and decreased agonist-induced increase in blood pressure \[[@B72-ijms-19-00073],[@B73-ijms-19-00073]\]. Second, the omentin-induced AMPK phosphorylation can also reduce the RAS/ERK signaling cascade, accompanied by reduction of cardiac hypertrophy \[[@B74-ijms-19-00073]\] and smooth muscle cell (SMC) proliferation \[[@B9-ijms-19-00073],[@B75-ijms-19-00073]\]. Third, studies demonstrated that omentin can promote the AMPK/AKT pathway directly by suppressing myocyte apoptosis in acute ischemic heart injury \[[@B76-ijms-19-00073]\] and decreasing the expression of proinflammatory mediators, including TNF-α, IL-6, and monocyte chemotactic protein-1 (MCP-1) in macrophages \[[@B77-ijms-19-00073]\].

Moreover, omentin protected against arterial calcification by inhibiting osteoblastic differentiation of calcifying vascular smooth muscle cells (CVSMCs) via the phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway \[[@B78-ijms-19-00073]\]. This may be associated with increased production of osteoprotegerin (OPG) and decreased receptor activation for nuclear factor κB ligand (RANKL) in both CVSMCs and osteoblasts \[[@B79-ijms-19-00073]\]. In addition, omentin promoted human osteoblast (hOB) proliferation through the PI3K/AKT signaling pathway \[[@B80-ijms-19-00073]\]. Importantly, omentin suppressed adhesion of monocytes to TNF-α-activated endothelial cells by inhibiting ICAM-1 and VCAM-1 expression via PI3K-AKT signaling and by blocking the ERK/NF-κB pathway \[[@B81-ijms-19-00073]\].

Furthermore, omentin inhibited VCAM-1 expression in vascular smooth muscle cells (VSMCs) via phosphorylation of p38 and JNK at least in part through preventing NADPH oxidase (NOX)-derived superoxide production; it also restrained TNF-α-induced adhesion of U937 monocytes to isolated rat VSMCs \[[@B82-ijms-19-00073]\]. Finally, omentin also inhibited NOX/O2-/p38/heat shock protein 27 (HSP27) pathways to prevent platelet-derived growth factor (PDGF-BB)-induced smooth muscle cell (SMC) migration, which may be related to its protective role in neointimal hyperplasia \[[@B83-ijms-19-00073]\].

5. Roles of Omentin in Pulmonary Disease {#sec5-ijms-19-00073}
========================================

5.1. Omentin in Malignant Pleural Mesothelioma (MPM) {#sec5dot1-ijms-19-00073}
----------------------------------------------------

Malignant pleural mesothelioma (MPM) is an uncommon but lethal tumor. The effect of current treatment on MPM is poor, and surgery is most effective for patients in early stage MPM. Unfortunately, because of the lack of characteristic clinical symptoms, radiographical features, and specific diagnostic markers for MPM, diagnosis of MPM at the early stage is difficult. The median survival after radical surgery or chemotherapy is only 9--12 months \[[@B84-ijms-19-00073],[@B85-ijms-19-00073]\].

A study suggested that both the mRNA and protein levels of omentin increased (\>129-fold increase) in mesothelioma tumors and cell lines \[[@B52-ijms-19-00073],[@B86-ijms-19-00073]\]. Epithelioid-type MPMs, but not lung adenocarcinomas with pleura invasion or adjacent reactive mesothelial cells, can be stained with anti-omentin antibodies. Moreover, patients with MPM possessed higher omentin levels than patients with lung cancer and pleural effusion; omentin concentration in pleural effusions of patients with MPM (MPM) is about 3000 ng/mL, while in lung cancer (LC), tuberculosis (TB), and pleuropneumonia (PP), the average levels of omentin are about 300, 250 and 650 ng/mL \[[@B86-ijms-19-00073]\], respectively. Studies demonstrated that except for some mucinous adenocarcinomas, omentin was not expressed in other cancers, such as biphasic synovial sarcoma, breast carcinoma, colon adenocarcinoma, epithelioid angiosarcoma, epithelioid hemangioendothelioma, gastric adenocarcinoma, lung cancer, ovarian adenocarcinoma, renal cell cancer, and urothelial cancer \[[@B87-ijms-19-00073]\]. Fortunately, mucinous adenocarcinomas can be easily distinguished from MPM by other methods \[[@B87-ijms-19-00073]\].

Therefore, these results suggested that omentin in the pleural effusion could be used as a specific diagnostic marker for distinguishing epithelioid-type MPMs from other carcinomas because of its specificity and the simplicity of pathological assessment.

5.2. Omentin in Asthma {#sec5dot2-ijms-19-00073}
----------------------

Asthma is a disease characterized by T-helper type 2 (Th2) allergic airway inflammation, airway hyperresponsiveness, mucus overproduction, and peribronchial fibrosis. Kuperman et al. demonstrated that omentin-1 expression was enhanced in ovalbumin (OVA) allergic mice and IL-13-overexpressing mice \[[@B64-ijms-19-00073]\]. They also showed that omentin mRNA was significantly upregulated in the airway epithelial cells from asthmatic individuals \[[@B64-ijms-19-00073]\]. IL-13 treatment increased omentin mRNA levels in cultured primary human bronchial epithelial cells and the mouse airway in vivo \[[@B88-ijms-19-00073]\]. Furthermore, omentin was up-regulated in the sputum of subjects with asthma \[[@B89-ijms-19-00073]\]. A study demonstrated that a single-nucleotide polymorphism in omentin was related to increased asthma risk \[[@B90-ijms-19-00073]\]. These observations indicated that omentin may play an important role in the pathogenesis of asthma.

Studies of mouse asthma models showed that IL-13 was necessary for allergen-induced airway inflammation, airway hyper responsiveness, and mucus production \[[@B91-ijms-19-00073],[@B92-ijms-19-00073]\]. IL-13 prompts the production of MCP-1 and MCP-3 in mouse lung tissue and human bronchial epithelial cells through the activation of p38, APK, ERK, and JAK-2 \[[@B93-ijms-19-00073]\]. Studies showed that MCP-1, MCP-3 and omentin levels were rapidly increased after access to airway allergens. Importantly, omentin was mainly expressed in airway mucous cells \[[@B94-ijms-19-00073]\]. Gu et al. \[[@B94-ijms-19-00073]\] also showed that the increase in MCP-1 and -3 mRNA levels were completely inhibited by omentin shRNA and galactose, which binds to omentin and inhibits its function \[[@B95-ijms-19-00073]\]. Moreover, inhibition of omentin expression also decreased the levels of secreted MCP-1 and -3 in vivo. In addition, eosinophil counts in bronchoalveolar lavage fluid (BALF) and inflammatory cell infiltration around airways in OVA-challenged mice were reversed by omentin knock-down \[[@B94-ijms-19-00073]\]. These data indicated that omentin was essential for IL-13-induced MCP-1 and MCP-3 expression in mouse lung epithelial cells and it promoted allergic airway inflammation. Furthermore, IL-25 and IL-33 levels were enhanced in asthma during innate immune response to allergens, and they play important roles at the onset of allergic inflammation in asthma \[[@B96-ijms-19-00073],[@B97-ijms-19-00073]\]. Studies demonstrated that omentin was involved in allergen-induced IL-25 and IL-33 production in asthma \[[@B98-ijms-19-00073]\]. These results indicated that omentin may participate in the pathogenesis of airway inflammation, airway hyper responsiveness, and mucus overproduction in asthma.

Furthermore, omentin may be a component of airway mucus. This may be conducive to forming pathologic mucus and defending against microbes. A study showed that omentin was a goblet cell protein, which is secreted with mucus into the intestinal lumen \[[@B87-ijms-19-00073]\]. In addition, other studies in the intestine have suggested that mucin--omentin interactions may alter the biophysical properties of mucus \[[@B99-ijms-19-00073]\]. As we know, bronchial inflammation can cause hyperplasia of goblet cells and enhances the production of mucus \[[@B100-ijms-19-00073]\]. In that way, prominent immunostaining for omentin in asthmatic mucus and the high concentrations of omentin in sputum of patients with acute severe asthma corroborate these observations \[[@B89-ijms-19-00073]\]. Moreover, omentin can also bind to lactoferrin in sputum. The binding of omentin to lactoferrin can be increased by galactofuranoside by which omentin interacts with lactoferrin to defend against microbes \[[@B89-ijms-19-00073]\].

5.3. Omentin in Obstructive Sleep Apnea Syndrome (OSAS) {#sec5dot3-ijms-19-00073}
-------------------------------------------------------

Obstructive sleep apnea syndrome (OSAS) is a widespread disease associated with snoring, witnessed apnea, repeated airway obstruction during sleep and excessive daytime sleepiness \[[@B101-ijms-19-00073],[@B102-ijms-19-00073]\], leading to resistance to airflow, oxygen desaturation, hypoxemia and oxidative stress \[[@B103-ijms-19-00073]\]. Studies demonstrated that inflammatory processes, oxidation, and endothelial dysfunction contributed to the occurrence and development of OSAS \[[@B104-ijms-19-00073],[@B105-ijms-19-00073]\]. Importantly, omentin increased endothelial NO expression, mitigated inflammation, and oxidation in human endothelial cells \[[@B70-ijms-19-00073],[@B71-ijms-19-00073]\]. However, studies for determining omentin levels in OSAS patients have yielded contradictory results \[[@B61-ijms-19-00073],[@B62-ijms-19-00073],[@B63-ijms-19-00073],[@B106-ijms-19-00073]\]. Two studies reported that omentin levels increased in patients with OSAS \[[@B62-ijms-19-00073],[@B63-ijms-19-00073]\], whereas the levels of omentin in plasma were reduced to normal values after continuous positive airway pressure (CPAP) therapy for three months, \[[@B63-ijms-19-00073]\]; unfortunately, the sample sizes used in these studies were small. Another study, which had a larger sample size, indicated that omentin levels decreased drastically in OSAS patients and correlated with the severity of OSAS \[[@B61-ijms-19-00073]\]. It also demonstrated that a low omentin level could be regarded as a specific diagnostic marker for the occurrence and deterioration of OSAS \[[@B61-ijms-19-00073]\]. Uygur et al. \[[@B106-ijms-19-00073]\] reported that the lower serum omentin level in OSAS can be reversed by CPAP treatment, which also confirmed the previous observations. More investigations are required to understand the exact roles and mechanisms of omentin in OSAS.

5.4. Omentin in Pulmonary Arterial Hypertension (PAH) {#sec5dot4-ijms-19-00073}
-----------------------------------------------------

Pulmonary arterial hypertension (PAH) is characterized by endothelial dysfunction, inflammation, and vascular remodeling, resulting in increased pulmonary vascular resistance and pulmonary pressure, finally causing right heart failure (RHF) \[[@B107-ijms-19-00073]\]. A series of epidemiological studies highlighted that omentin levels were inversely correlated with obesity, T2DM, and hypertension \[[@B16-ijms-19-00073],[@B108-ijms-19-00073]\]. Moreover, studies showed that omentin levels were extremely low in patients with OSAS and correlated with the severity of OSAS \[[@B61-ijms-19-00073],[@B106-ijms-19-00073]\], which may ultimately induce PAH and RHF. Kazama et al. \[[@B72-ijms-19-00073],[@B108-ijms-19-00073]\] observed that omentin suppressed agonist-induced rise in blood pressure (BP) and monocrotaline-induced enhancement in PA pressure. Additionally, omentin can vasodilate isolated blood vessel via stimulation of endothelium-dependent NO production \[[@B109-ijms-19-00073]\].

A previous study revealed that omentin exerted an anti-inflammatory effect on vascular endothelial cells by preventing TNF-α-induced COX-2 expression via inhibiting AMPK/eNOS/NO pathways \[[@B70-ijms-19-00073]\]. Omentin may inhibit expression of the adhesion molecules ICAM-1 and VCAM-1 in endothelial cells \[[@B81-ijms-19-00073]\]. Moreover, omentin played an anti-inflammatory role by inhibiting VCAM-1 in SMCs via inhibition of superoxide production and p38/JNK activation \[[@B82-ijms-19-00073]\]. Importantly, a significant amount of inflammation is necessary for the occurrence and development of structural remodeling in PAH. Kazama et al. \[[@B83-ijms-19-00073]\] also showed that omentin can prevent neointimal hyperplasia via suppression of SMC migration, which was essential for the progression of vascular structural remodeling. Another study also indicated that omentin notably restrained MCT-induced right ventricular hypertrophy \[[@B108-ijms-19-00073]\].

The above evidence suggested that omentin mitigated PAH via suppression of inflammation, SMC migration, and vascular structural remodeling. Thus, omentin possesses potential as a therapeutic tool for PAH and RHF.

5.5. Omentin in Acute Respiratory Distress Syndrome (ARDS) {#sec5dot5-ijms-19-00073}
----------------------------------------------------------

Acute respiratory distress syndrome (ARDS), a devastating disorder distinguished by inflammatory response and endothelial barrier disruption with a 30--60% mortality rate \[[@B110-ijms-19-00073],[@B111-ijms-19-00073]\], is characterized by inflammatory injury, lung edema, and refractory hypoxemia \[[@B112-ijms-19-00073]\]. Studies suggested that omentin can vasodilate isolated blood vessels, suppress the expression of adhesion molecules, and inhibit inflammation in vascular endothelial cells \[[@B70-ijms-19-00073],[@B81-ijms-19-00073],[@B109-ijms-19-00073]\]. Thus, these studies indicated that omentin may play anti-inflammatory and vascular-protective roles in mitigating obesity-related vascular complications.

In addition, direct evidence regarding the impact of omentin on ARDS has also been found. Qi et al. \[[@B59-ijms-19-00073]\] observed that the levels of omentin in ARDS individuals were related to inflammatory responses, and that over-expression of omentin can reduce the expression of IL-6 and TNF-α and attenuate the activation of the NF-κB Rel subunit, thus alleviating pulmonary inflammation in mouse lung tissue. Furthermore, omentin can reduce the levels of IL-6, TNF-α, and VCAM-1 by suppressing NF-κB activation in primary ECs isolated from the lungs or human pulmonary microvascular endothelial cells. Furthermore, omentin can improve pulmonary endothelial cell survival and differentiation, protect pulmonary endothelial barrier function, and decrease the pulmonary microvascular permeability in LPS-induced ARDS models. These results demonstrated that omentin protected the pulmonary endothelial barrier and alleviated pulmonary inflammation by activating the PI3K Akt/eNOS-dependent pathway in LPS-induced ARDS mouse \[[@B59-ijms-19-00073]\]. Thus, omentin may be approved as an effective therapeutic tool for ARDS in the future.

5.6. Omentin in Chronic Obstructive Pulmonary Disease (COPD) {#sec5dot6-ijms-19-00073}
------------------------------------------------------------

Progressive airflow obstruction, destruction of lung parenchyma, and lung inflammation are the characteristic features of COPD, which is a common chronic respiratory disease. Convincing evidence suggested that cigarette smoking (CS) is the major risk factor for COPD \[[@B113-ijms-19-00073],[@B114-ijms-19-00073]\]. Carolan et al. used a microarray screen, TaqMan real time-polymerase chain reaction (RT-PCR), and Western blot analysis to determine whether omentin expression decreased in the airway epithelium of healthy smokers, smokers with lone emphysema, and smokers with established COPD \[[@B60-ijms-19-00073]\]. It is well-known that omentin plays a significant role in the identification of bacterial compositions and pathogens because of its affinity for galactofuranosyl residues \[[@B12-ijms-19-00073],[@B13-ijms-19-00073]\]. Since both active and passive smoke exposure is linked to respiratory infections \[[@B115-ijms-19-00073]\], omentin may be useful to detect bacterial infections in smokers/passive smokers with COPD. Extensive investigations are warranted to dissect the precise molecular mechanisms of omentin in smokers and the onset and progression of COPD.

6. Discussion and Conclusions {#sec6-ijms-19-00073}
=============================

Fluctuating omentin levels are widely associated with various diseases, including obesity, diabetes, cardiovascular disease, autoimmune disease, various malignant tumors, reproduction system diseases, nervous system diseases, and pulmonary diseases. Omentin can regulate inflammation status, vasomotor and endothelium function, proliferation, apoptosis, and differentiation of cell types via various molecular mechanisms.

Nonetheless, the mechanism via which omentin regulates various physiological and pathological functions is not completely elucidated. At present, the specific receptor for omentin is still unknown, which makes understanding the physiological function of omentin difficult.

Omentin may play significant roles in pulmonary diseases, such as MPM, asthma, OSAS, PAH, ARDS, COPD, and other lung disorders. Omentin in the pleural effusion may be a specific diagnostic marker for MPM, which is conducive for diagnosing MPM in the early stage, extending the median survival of patients with MPM. Omentin, which belongs to the category of "good" adipokine, exerts anti-inflammatory effects in various physiological and pathological processes. However, current studies have shown that omentin may participate in the pathogenesis of asthma. Omentin is essential for the expression of inflammatory factors in lung epithelial cells, which facilitate allergic airway inflammation, and it may be a component of airway mucus that contributes to pathologic mucus formation in asthma. Omentin levels were drastically reduced in patients with OSAS, which correlated with the severity of OSAS. Moreover, omentin can elicit anti-inflammatory and anti-migratory effects and inhibit vascular structural remodeling for PAH and RHF. Furthermore, omentin can protect pulmonary endothelial barrier function and decrease pulmonary microvascular permeability and inflammation in LPS-induced ARDS models. This indicated that omentin may act as an anti-inflammatory therapeutic drug for ARDS. Studies demonstrated that omentin levels decreased in the airway epithelium of healthy smokers, which is a major risk factor for infections and COPD. This suggests that omentin may contribute to defense against respiratory tract infections and COPD.

Extensive investigations are required to explore the effect of omentin in respiratory diseases. Whether omentin can be used for the diagnosis and assessment of intervention outcomes or development of new therapeutic targets requires further investigation. We expect this review to be helpful for a better understanding of the biological role of omentin in respiratory diseases.
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T2DM

type-2 diabetes mellitus

PCOS

polycystic ovary syndrome

CAD

coronary artery disease

EAT

epicardial adipose tissue

NAFLD

nonalcoholic fatty liver disease

SLE

systemic lupus erythematosus

HIV/HAART

human immunodeficiency virus/highly active anti-retroviral therapy

MPM

malignant pleural mesothelioma

ARDS

acute respiratory distress syndrome

OSAS

obstructive sleep apnoea syndrome

COX-2

cyclooxygenase-2

AMPK

Adenosine 5′-monophosphate-activated protein kinase

eNOS

endothelial nitric oxide synthase

JNK

Jun N-Terminal Kinase

SMC

smooth muscle cell

MCP-1

monocyte chemotactic protein-1

CVSMCs

calcifying vascular smooth muscle cells

PI3K/Akt

phosphatidylinositol 3 kinase/protein kinase B

OPG

osteoprotegerin

RANKL

nuclear factor κB ligand

hOB

human osteoblast

NOX

NADPH oxidase

PDGF-BB

platelet-derived growth factor

OVA

ovalbumin

CPAP

continuous positive airway pressure

COPD

chronic obstructive pulmonary disease
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###### 

Fluctuation of omentin levels in various diseases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diseases                                   Fluctuation of Omentin Levels in Various Sample   Omentin-1 Concentration (ng/mL)\             *p* Value                  Ref.                                                  
                                                                                               Mean (Range) or Mean ± SD                                                                                                     
  ------------------------------------------ ------------------------------------------------- -------------------------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  Obesity-related diseases                   Obesity                                           Serum ↓                                      370 ± 20                   310 ± 20                   0.009                      \[[@B16-ijms-19-00073]\]

  Pregnant with preexisting obesity          Cord ↓                                            58.0 ± 6.0                                   48.3 ± 9.0                 \>0.05                     \[[@B19-ijms-19-00073]\]   

  Maternal ↓                                 19.5 ± 2.3                                        7.1 ± 0.9                                    \<0.05                                                                           

  T2DM                                       Serum ↓                                           18.85 ± 3.23                                 16.12 ± 4.08               \<0.05                     \[[@B20-ijms-19-00073]\]   

  GDM with obesity                           Serum ↓                                           355.94 ± 42.61                               216.41 ± 51.33             0.000                      \[[@B21-ijms-19-00073]\]   

  T2DM with ischemic heart disease           Serum ↓                                           12.44 ± 2.12                                 10.31 ± 2.35               0.038                      \[[@B23-ijms-19-00073]\]   

  T2DM with Diabetic Retinopathy             Serum ↓                                           208.31 (164.20--251.20)                      139.96 (119.28--157.87)    \<0.001                    \[[@B24-ijms-19-00073]\]   

  Vitreous ↓                                 96.00 (75.24--112.64)                             50.36 (39.91--57.73)                         \<0.001                                                                          

  PCOS                                       Serum ↓                                           269.7                                        197.6                      0.0073                     \[[@B25-ijms-19-00073]\]   

  515.9                                      210.5                                             \<0.001                                      \[[@B26-ijms-19-00073]\]                                                         

  27.6                                       23.7                                              0.05                                         \[[@B28-ijms-19-00073]\]                                                         

  Coronary artery disease                    Serum ↓                                           659.39                                       373.71                     \<0.001                    \[[@B29-ijms-19-00073]\]   

  815.3 ± 185.32                             518.61 ± 191.10                                   \<0.001                                      \[[@B30-ijms-19-00073]\]                                                         

  34.58 ± 4.23                               10.66 ± 3.41                                      \<0.01                                       \[[@B31-ijms-19-00073]\]                                                         

  254.00 ± 72.98                             113.08 ± 61.43                                    \<0.0001                                     \[[@B33-ijms-19-00073]\]                                                         

  EAT ↑ (mRNA)                               0.76 (0.71--0.89)                                 1.25 (1.10--2.85)                            0.002                      \[[@B32-ijms-19-00073]\]                              

  coronary heart disease                     Serum ↓                                           1.115 ± 0.361                                0.718 ± 0.229              0.000                      \[[@B34-ijms-19-00073]\]   

  Dilated cardiomyopathy                     Serum ↓                                           233.33 ± 58.04                               153.00 ± 48.94             \<0.01                     \[[@B35-ijms-19-00073]\]   

  NAFLD                                      Serum ↑                                           376 ± 196                                    460 ± 181                  \<0.001                    \[[@B36-ijms-19-00073]\]   

  Chronic immune or inflammatory disease     Psoriasis                                         Serum ↓                                      26.8 ± 14.2                18.5 ± 13.1                0.0053                     \[[@B37-ijms-19-00073]\]

  488.7 ± 190.3                              354.2 ± 152.0                                     0.001                                        \[[@B38-ijms-19-00073]\]                                                         

  143.60 ± 48.97                             95.61 ± 44.38                                     0.001                                        \[[@B39-ijms-19-00073]\]                                                         

  Rheumatoid arthritis                       Serum ↓                                           23.58 (14.60--28.39)                         19.98 (11.98--27.21)       \>0.01                     \[[@B41-ijms-19-00073]\]   

  Behcet disease                             Serum ↓                                           12.4 ± 6.24                                  8.9 ± 4.65                 0.035                      \[[@B42-ijms-19-00073]\]   

  Crohn's disease                            Serum ↓                                           409.40 ± 215.65                              201.29 ± 76.65             \<0.0001                   \[[@B43-ijms-19-00073]\]   

  Ulcerative colitis                         Serum ↓                                           28.62 (24.71--33.21)                         14.74 (11.52--18.16)       \<0.001                    \[[@B44-ijms-19-00073]\]   

  Chronic periodontitis                      Gingival\                                         135                                          45                         \<0.008                    \[[@B45-ijms-19-00073]\]   
                                             crevicular fluid ↓                                                                                                                                                              

  Acute pancreatitis                         Serum ↑                                           22.49 ± 1.4                                  37.79 ± 1.24               \<0.01                     \[[@B46-ijms-19-00073]\]   

  Chronic pancreatitis                       Serum ↑                                           22.49 ± 1.4                                  49.37 ± 2.82               \<0.01                     \[[@B46-ijms-19-00073]\]   

  Psoriasis arthritis                        Serum ↑                                           4                                            20.6 (2.8--82.2)           0.01                       \[[@B47-ijms-19-00073]\]   

  SLE patients with nephritis                Serum ↑                                           11.42 (1.44--26.35)                          30.77 (16.77--37.63)       0.002                      \[[@B48-ijms-19-00073]\]   

  HALS                                       Serum ↓                                           \-                                           \-                         0.001                      \[[@B49-ijms-19-00073]\]   

  Temporo-mandibular disorders               Serum ↓                                           464.8 ± 191.8                                413.5 ±145.9               0.072                      \[[@B50-ijms-19-00073]\]   

  Tumor diseases                             Renal cell cancer                                 Serum ↓                                      9.86 ± 1.44                3.62 ± 0.76                \<0.001                    \[[@B51-ijms-19-00073]\]

  MPM                                        tumor tissues ↑                                   Serial analysis of gene expression (SAGE)\   \-                         \[[@B52-ijms-19-00073]\]                              
                                                                                               \>129 flod increase                                                                                                           

  Prostate cancer                            Serum ↑                                           373 (207--792)                               546.8 (297.1--945.7)       \<0.001                    \[[@B54-ijms-19-00073]\]   

  colon and colorectal cancer                Serum ↑                                           0.376 (0.155--0.662)                         0.618 (0.151--0.758)       \<0.001                    \[[@B56-ijms-19-00073]\]   

  Gastric cancer                             Tumor tissues ↑\                                  qRT-PCR \> 6 flod increase                   \<0.001                    \[[@B57-ijms-19-00073]\]                              
                                             (mRNA)                                                                                                                                                                          

  Pancreatic adenocarcinoma                  Serum ↑                                           1.61 (0.80--4.98)                            9.57 (3.62--21.948)        \<0.001                    \[[@B58-ijms-19-00073]\]   

  Respiratory diseases                       ARDS                                              Serum ↓                                      \-                         \-                         \<0.05                     \[[@B59-ijms-19-00073]\]

  Smokers                                    airway epithelium ↓\                              TaqMan RT-PCR and Immunohistochemistry\      \<0.05                     \[[@B60-ijms-19-00073]\]                              
                                             (mRNA/protein)                                    3.8--14.7 fold decrease                                                                                                       

  OSAS (controversial)                       Serum ↓                                           22.62 (18.71--27.21)                         11.29 (8.02--15.13)        \<0.001                    \[[@B61-ijms-19-00073]\]   

  Serum ↑                                    432.0 (155.2--1101.2)                             570.8 (288.4--2152.4)                        \<0.001                    \[[@B62-ijms-19-00073]\]                              

  Serum ↑                                    9.24 ± 4.85                                       17.78 ± 7.20                                 \<0.05                     \[[@B63-ijms-19-00073]\]                              

  Asthma                                     Airway epithelial ↑ (mRNA)                        Arrays and PCR\                              \-                         \[[@B64-ijms-19-00073]\]                              
                                                                                               7.6 and 9.5 flod increase                                                                                                     

  Others                                     Liver cirrhosis                                   Portal venous serum ↑                        \-                         \-                         0.005                      \[[@B66-ijms-19-00073]\]

  hepatic venous seru ↑                      \-                                                \-                                           0.027                                                                            

  systemic venous serum ↑                    \-                                                \-                                           0.032                                                                            

  Anorexia nervosa                           Serum ↑                                           185.39 ± 13.98                               218.53 ± 18.17             \<0.0001                   \[[@B67-ijms-19-00073]\]   

  34.3 ± 2.6                                 46.1 ± 3.8                                        \<0.0001                                     \[[@B68-ijms-19-00073]\]                                                         

  End stage renal disease in haemodialysis   Serum ↑                                           357.5 ±147.4                                 606.6 ±313.0               \<0.001                    \[[@B69-ijms-19-00073]\]   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARDS, acute respiratory distress syndrome; GDM, gestational diabetes mellitus; HALS, human immunodeficiency virus/highly active anti-retroviral therapy (HIV/HAART)-associated lipodystrophy syndrome; MPM, malignant pleural mesothelioma; NAFLD, nonalcoholic fatty liver disease; OSAS, obstructive sleep apnoea syndrome; PCOS, polycystic ovary syndrome; SD, Standard Deviation; SLE, systemic lupus erythematosus; T2DM, type-2 diabetes mellitus; Ref., Reference; ↑ = increase, ↓ = decrease, "-" =exact data cannot get from the papers.
